| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Stimulants | 70 | 2025 | 233 | 16.950 |
Why?
|
| Hallucinogens | 37 | 2024 | 83 | 16.730 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 31 | 2024 | 74 | 13.010 |
Why?
|
| Dextroamphetamine | 55 | 2024 | 108 | 11.600 |
Why?
|
| Emotions | 46 | 2024 | 372 | 10.820 |
Why?
|
| Methamphetamine | 27 | 2025 | 104 | 10.200 |
Why?
|
| Affect | 94 | 2025 | 396 | 10.000 |
Why?
|
| Ethanol | 55 | 2024 | 273 | 9.130 |
Why?
|
| Dronabinol | 27 | 2024 | 58 | 9.000 |
Why?
|
| Double-Blind Method | 135 | 2025 | 1729 | 7.980 |
Why?
|
| Reward | 42 | 2025 | 209 | 7.890 |
Why?
|
| Alcohol Drinking | 42 | 2023 | 283 | 7.350 |
Why?
|
| Impulsive Behavior | 37 | 2024 | 290 | 6.210 |
Why?
|
| Social Behavior | 25 | 2024 | 307 | 6.020 |
Why?
|
| Lysergic Acid Diethylamide | 8 | 2024 | 27 | 5.690 |
Why?
|
| Substance-Related Disorders | 39 | 2025 | 441 | 5.690 |
Why?
|
| Stress, Psychological | 20 | 2018 | 342 | 5.670 |
Why?
|
| Young Adult | 126 | 2025 | 6930 | 5.140 |
Why?
|
| Amphetamine | 16 | 2024 | 101 | 4.670 |
Why?
|
| Adult | 250 | 2025 | 27918 | 4.610 |
Why?
|
| Behavior, Addictive | 21 | 2023 | 137 | 4.580 |
Why?
|
| Cues | 17 | 2025 | 186 | 4.390 |
Why?
|
| Choice Behavior | 25 | 2021 | 159 | 4.360 |
Why?
|
| Psychotropic Drugs | 14 | 2024 | 82 | 4.220 |
Why?
|
| Heart Rate | 41 | 2024 | 505 | 4.140 |
Why?
|
| Male | 248 | 2025 | 44557 | 3.590 |
Why?
|
| Motivation | 25 | 2023 | 310 | 3.560 |
Why?
|
| Psychomotor Performance | 41 | 2022 | 497 | 3.520 |
Why?
|
| Dose-Response Relationship, Drug | 67 | 2024 | 1914 | 3.520 |
Why?
|
| Alcoholism | 18 | 2023 | 188 | 3.480 |
Why?
|
| Euphoria | 20 | 2025 | 47 | 3.440 |
Why?
|
| Adolescent | 111 | 2024 | 9606 | 3.420 |
Why?
|
| Female | 236 | 2025 | 48702 | 3.390 |
Why?
|
| Humans | 325 | 2025 | 93515 | 3.340 |
Why?
|
| Blood Pressure | 36 | 2021 | 896 | 3.170 |
Why?
|
| Personality | 15 | 2021 | 140 | 3.110 |
Why?
|
| Oxytocin | 9 | 2023 | 75 | 3.060 |
Why?
|
| Smoking | 17 | 2020 | 648 | 3.010 |
Why?
|
| Cannabis | 6 | 2023 | 38 | 2.980 |
Why?
|
| Brain | 29 | 2025 | 2391 | 2.840 |
Why?
|
| Hydrocortisone | 23 | 2018 | 296 | 2.660 |
Why?
|
| Attention | 19 | 2019 | 411 | 2.660 |
Why?
|
| Caffeine | 14 | 2017 | 85 | 2.650 |
Why?
|
| Anxiety | 18 | 2021 | 337 | 2.540 |
Why?
|
| Healthy Volunteers | 23 | 2024 | 148 | 2.270 |
Why?
|
| Analgesics, Opioid | 10 | 2024 | 513 | 2.230 |
Why?
|
| Arousal | 27 | 2021 | 171 | 2.220 |
Why?
|
| Cognition | 17 | 2022 | 627 | 2.200 |
Why?
|
| Cannabinoid Receptor Agonists | 6 | 2023 | 11 | 2.140 |
Why?
|
| Psychopharmacology | 4 | 2023 | 26 | 2.090 |
Why?
|
| Facial Expression | 6 | 2024 | 58 | 2.060 |
Why?
|
| Mental Recall | 7 | 2023 | 173 | 2.010 |
Why?
|
| Polymorphism, Single Nucleotide | 26 | 2020 | 2484 | 1.990 |
Why?
|
| Individuality | 18 | 2025 | 114 | 1.960 |
Why?
|
| Cannabinoids | 5 | 2023 | 16 | 1.950 |
Why?
|
| Smokers | 5 | 2022 | 54 | 1.870 |
Why?
|
| Risk-Taking | 10 | 2020 | 158 | 1.820 |
Why?
|
| Central Nervous System Depressants | 9 | 2020 | 45 | 1.800 |
Why?
|
| Cross-Over Studies | 22 | 2025 | 390 | 1.780 |
Why?
|
| Hypnotics and Sedatives | 9 | 2023 | 137 | 1.760 |
Why?
|
| Photic Stimulation | 14 | 2019 | 509 | 1.740 |
Why?
|
| Craving | 4 | 2021 | 24 | 1.740 |
Why?
|
| Reaction Time | 20 | 2022 | 317 | 1.710 |
Why?
|
| Surveys and Questionnaires | 41 | 2020 | 2802 | 1.680 |
Why?
|
| Memory | 7 | 2017 | 227 | 1.630 |
Why?
|
| Dopamine Uptake Inhibitors | 5 | 2013 | 43 | 1.570 |
Why?
|
| Buprenorphine | 4 | 2024 | 52 | 1.570 |
Why?
|
| Memory, Episodic | 5 | 2023 | 62 | 1.550 |
Why?
|
| Smoking Cessation | 12 | 2022 | 269 | 1.500 |
Why?
|
| Nucleus Accumbens | 4 | 2023 | 113 | 1.480 |
Why?
|
| Self Report | 10 | 2020 | 328 | 1.480 |
Why?
|
| Menstrual Cycle | 9 | 2022 | 59 | 1.450 |
Why?
|
| Amygdala | 5 | 2019 | 86 | 1.440 |
Why?
|
| Progesterone | 9 | 2011 | 112 | 1.430 |
Why?
|
| Nicotine | 8 | 2022 | 208 | 1.390 |
Why?
|
| Analysis of Variance | 29 | 2017 | 884 | 1.340 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2025 | 3476 | 1.330 |
Why?
|
| Alcohol-Related Disorders | 3 | 2020 | 18 | 1.320 |
Why?
|
| Narcotic Antagonists | 8 | 2016 | 170 | 1.320 |
Why?
|
| Diazepam | 13 | 2006 | 26 | 1.290 |
Why?
|
| Empathy | 5 | 2021 | 150 | 1.280 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2024 | 125 | 1.270 |
Why?
|
| Behavior | 13 | 2015 | 85 | 1.250 |
Why?
|
| Mental Disorders | 7 | 2024 | 455 | 1.240 |
Why?
|
| Facial Recognition | 3 | 2024 | 17 | 1.220 |
Why?
|
| Speech | 4 | 2015 | 90 | 1.210 |
Why?
|
| Attentional Bias | 4 | 2019 | 10 | 1.200 |
Why?
|
| Conditioning, Classical | 4 | 2017 | 38 | 1.180 |
Why?
|
| Follicular Phase | 5 | 2022 | 11 | 1.150 |
Why?
|
| Tobacco Products | 2 | 2020 | 77 | 1.140 |
Why?
|
| Naltrexone | 8 | 2022 | 139 | 1.140 |
Why?
|
| Alcoholic Beverages | 2 | 2020 | 12 | 1.130 |
Why?
|
| Delay Discounting | 5 | 2019 | 8 | 1.100 |
Why?
|
| Interpersonal Relations | 4 | 2024 | 177 | 1.100 |
Why?
|
| Brain Mapping | 12 | 2021 | 569 | 1.030 |
Why?
|
| Anticipation, Psychological | 3 | 2023 | 10 | 1.020 |
Why?
|
| Antidepressive Agents | 2 | 2018 | 109 | 1.020 |
Why?
|
| Psychological Tests | 9 | 2020 | 88 | 1.000 |
Why?
|
| Electroencephalography | 4 | 2024 | 797 | 0.990 |
Why?
|
| Estradiol | 7 | 2023 | 247 | 0.980 |
Why?
|
| Anti-Anxiety Agents | 4 | 2017 | 23 | 0.980 |
Why?
|
| Genotype | 16 | 2019 | 1866 | 0.960 |
Why?
|
| Schizophrenia | 5 | 2023 | 529 | 0.950 |
Why?
|
| Amphetamines | 2 | 2024 | 18 | 0.940 |
Why?
|
| Marijuana Smoking | 8 | 2019 | 28 | 0.920 |
Why?
|
| Limbic System | 1 | 2025 | 25 | 0.920 |
Why?
|
| Gyrus Cinguli | 4 | 2019 | 49 | 0.910 |
Why?
|
| Dopamine | 9 | 2025 | 276 | 0.890 |
Why?
|
| Amphetamine-Related Disorders | 6 | 2018 | 29 | 0.890 |
Why?
|
| Social Environment | 7 | 2014 | 194 | 0.860 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2013 | 68 | 0.850 |
Why?
|
| Saliva | 8 | 2017 | 124 | 0.850 |
Why?
|
| Sleep | 8 | 2022 | 448 | 0.840 |
Why?
|
| Administration, Oral | 11 | 2025 | 657 | 0.810 |
Why?
|
| Tobacco Use Disorder | 7 | 2021 | 121 | 0.800 |
Why?
|
| Apathy | 1 | 2023 | 7 | 0.800 |
Why?
|
| Memory Consolidation | 2 | 2023 | 15 | 0.760 |
Why?
|
| Polymorphism, Genetic | 9 | 2012 | 826 | 0.750 |
Why?
|
| Fear | 5 | 2014 | 88 | 0.750 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2013 | 53 | 0.750 |
Why?
|
| Alcoholic Intoxication | 5 | 2013 | 37 | 0.740 |
Why?
|
| Touch Perception | 2 | 2019 | 32 | 0.730 |
Why?
|
| Homeostasis | 1 | 2024 | 460 | 0.720 |
Why?
|
| Administration, Intranasal | 7 | 2020 | 140 | 0.710 |
Why?
|
| Parasympathetic Nervous System | 1 | 2021 | 33 | 0.700 |
Why?
|
| Dopamine Antagonists | 4 | 2005 | 33 | 0.700 |
Why?
|
| Task Performance and Analysis | 3 | 2013 | 92 | 0.690 |
Why?
|
| Sympathetic Nervous System | 1 | 2021 | 99 | 0.680 |
Why?
|
| Ventral Striatum | 1 | 2020 | 6 | 0.670 |
Why?
|
| Nicotinic Agonists | 2 | 2012 | 73 | 0.670 |
Why?
|
| Body Mass Index | 4 | 2019 | 811 | 0.660 |
Why?
|
| Placebos | 10 | 2013 | 206 | 0.640 |
Why?
|
| Fatigue | 6 | 2009 | 181 | 0.640 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 6 | 0.630 |
Why?
|
| Drug Tolerance | 5 | 2015 | 59 | 0.630 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 158 | 0.620 |
Why?
|
| Neuropsychological Tests | 9 | 2019 | 543 | 0.610 |
Why?
|
| Decision Making | 7 | 2022 | 674 | 0.610 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 2 | 2016 | 5 | 0.600 |
Why?
|
| GABA Agonists | 3 | 2006 | 18 | 0.600 |
Why?
|
| Neostriatum | 1 | 2019 | 23 | 0.590 |
Why?
|
| Cigarette Smoking | 2 | 2019 | 47 | 0.590 |
Why?
|
| Animals | 32 | 2025 | 28155 | 0.590 |
Why?
|
| Genome-Wide Association Study | 14 | 2020 | 1762 | 0.590 |
Why?
|
| Haloperidol | 3 | 2005 | 29 | 0.590 |
Why?
|
| Stress, Physiological | 2 | 2020 | 246 | 0.580 |
Why?
|
| Benzodiazepines | 2 | 2018 | 56 | 0.570 |
Why?
|
| Hormones | 2 | 2010 | 136 | 0.570 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2018 | 9 | 0.570 |
Why?
|
| Psychiatric Status Rating Scales | 10 | 2013 | 502 | 0.570 |
Why?
|
| Serotonin Agents | 2 | 2015 | 13 | 0.570 |
Why?
|
| Economics, Behavioral | 3 | 2019 | 7 | 0.560 |
Why?
|
| Receptors, Dopamine | 2 | 2010 | 32 | 0.550 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2017 | 13 | 0.540 |
Why?
|
| Pregnanolone | 5 | 2012 | 8 | 0.540 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 51 | 0.540 |
Why?
|
| Time Factors | 18 | 2015 | 5410 | 0.540 |
Why?
|
| Endophenotypes | 1 | 2017 | 19 | 0.540 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 149 | 0.530 |
Why?
|
| Food Preferences | 1 | 2017 | 27 | 0.520 |
Why?
|
| Narcotics | 1 | 2018 | 72 | 0.520 |
Why?
|
| Phenotype | 11 | 2020 | 2544 | 0.520 |
Why?
|
| Taste | 1 | 2017 | 29 | 0.520 |
Why?
|
| Sexual Behavior | 1 | 2020 | 328 | 0.510 |
Why?
|
| Sleep Deprivation | 2 | 2008 | 125 | 0.510 |
Why?
|
| Models, Psychological | 6 | 2018 | 164 | 0.510 |
Why?
|
| Oxycodone | 3 | 2014 | 35 | 0.500 |
Why?
|
| Evoked Potentials | 3 | 2022 | 194 | 0.500 |
Why?
|
| Food | 2 | 2010 | 92 | 0.500 |
Why?
|
| Bupropion | 3 | 2008 | 21 | 0.500 |
Why?
|
| Depression | 4 | 2018 | 544 | 0.500 |
Why?
|
| Language | 1 | 2018 | 158 | 0.500 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 190 | 0.490 |
Why?
|
| Oxygen | 4 | 2017 | 769 | 0.490 |
Why?
|
| Virtual Reality | 1 | 2017 | 37 | 0.480 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 10 | 0.480 |
Why?
|
| Visual Cortex | 1 | 2019 | 246 | 0.470 |
Why?
|
| Receptor, Adenosine A2A | 4 | 2010 | 16 | 0.470 |
Why?
|
| Space Perception | 1 | 2017 | 112 | 0.460 |
Why?
|
| Insulins | 1 | 2015 | 7 | 0.460 |
Why?
|
| Drug-Seeking Behavior | 2 | 2016 | 12 | 0.460 |
Why?
|
| Personality Tests | 9 | 2019 | 21 | 0.460 |
Why?
|
| Social Perception | 1 | 2016 | 92 | 0.450 |
Why?
|
| Motor Activity | 2 | 2017 | 323 | 0.450 |
Why?
|
| Association | 1 | 2015 | 5 | 0.450 |
Why?
|
| Insulin Infusion Systems | 1 | 2015 | 44 | 0.440 |
Why?
|
| Oxytocics | 3 | 2020 | 25 | 0.440 |
Why?
|
| Triazolam | 3 | 1999 | 5 | 0.430 |
Why?
|
| Sex Characteristics | 8 | 2013 | 333 | 0.430 |
Why?
|
| Overweight | 1 | 2015 | 120 | 0.430 |
Why?
|
| Conditioning, Operant | 4 | 2006 | 68 | 0.420 |
Why?
|
| Mecamylamine | 2 | 2005 | 4 | 0.420 |
Why?
|
| Hyperglycemia | 1 | 2015 | 181 | 0.420 |
Why?
|
| Neural Pathways | 5 | 2020 | 322 | 0.420 |
Why?
|
| Social Isolation | 3 | 2024 | 71 | 0.420 |
Why?
|
| Area Under Curve | 5 | 2016 | 335 | 0.410 |
Why?
|
| Semantics | 1 | 2014 | 55 | 0.410 |
Why?
|
| Breath Tests | 9 | 2018 | 58 | 0.410 |
Why?
|
| Drinking Behavior | 2 | 2010 | 13 | 0.400 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2017 | 184 | 0.400 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 20 | 0.390 |
Why?
|
| Behavior, Animal | 5 | 2013 | 390 | 0.390 |
Why?
|
| Veterans | 2 | 2024 | 99 | 0.390 |
Why?
|
| Theobromine | 1 | 2013 | 3 | 0.390 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2009 | 57 | 0.380 |
Why?
|
| Extinction, Psychological | 3 | 2017 | 21 | 0.380 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 379 | 0.380 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2010 | 4 | 0.370 |
Why?
|
| Marijuana Abuse | 3 | 2019 | 29 | 0.370 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2009 | 6 | 0.370 |
Why?
|
| Brain Chemistry | 4 | 2008 | 120 | 0.370 |
Why?
|
| Ethanolamines | 1 | 2012 | 24 | 0.370 |
Why?
|
| Genetic Variation | 7 | 2014 | 1415 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2019 | 2465 | 0.370 |
Why?
|
| Expressed Emotion | 1 | 2012 | 6 | 0.370 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2010 | 37 | 0.360 |
Why?
|
| Memory, Short-Term | 4 | 2020 | 242 | 0.360 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 168 | 0.360 |
Why?
|
| Principal Component Analysis | 3 | 2020 | 167 | 0.360 |
Why?
|
| Executive Function | 1 | 2012 | 103 | 0.360 |
Why?
|
| Quinoxalines | 1 | 2012 | 51 | 0.350 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2495 | 0.350 |
Why?
|
| Middle Aged | 28 | 2024 | 27573 | 0.350 |
Why?
|
| Sex Factors | 6 | 2017 | 1105 | 0.350 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.350 |
Why?
|
| Drug Users | 3 | 2019 | 29 | 0.350 |
Why?
|
| Personality Inventory | 9 | 2017 | 111 | 0.350 |
Why?
|
| Pleasure | 3 | 2020 | 14 | 0.340 |
Why?
|
| Discrimination Learning | 1 | 2011 | 63 | 0.340 |
Why?
|
| Eye Movements | 1 | 2012 | 119 | 0.340 |
Why?
|
| Postmenopause | 2 | 2002 | 106 | 0.340 |
Why?
|
| Communication | 3 | 2023 | 434 | 0.330 |
Why?
|
| Cocaine | 1 | 2011 | 79 | 0.330 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2010 | 8 | 0.330 |
Why?
|
| Gene Frequency | 7 | 2017 | 700 | 0.330 |
Why?
|
| Reproducibility of Results | 8 | 2020 | 2715 | 0.330 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2010 | 4 | 0.320 |
Why?
|
| Parietal Lobe | 2 | 2023 | 115 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 589 | 0.320 |
Why?
|
| Testosterone | 1 | 2011 | 259 | 0.320 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 33 | 0.310 |
Why?
|
| Amidohydrolases | 1 | 2009 | 17 | 0.310 |
Why?
|
| Linear Models | 3 | 2017 | 413 | 0.310 |
Why?
|
| Minisatellite Repeats | 2 | 2006 | 23 | 0.300 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 24 | 0.300 |
Why?
|
| Neuroimaging | 4 | 2020 | 132 | 0.300 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1847 | 0.300 |
Why?
|
| Self Administration | 7 | 2015 | 76 | 0.300 |
Why?
|
| Risk Assessment | 3 | 2012 | 2441 | 0.300 |
Why?
|
| Psychology | 1 | 2009 | 26 | 0.300 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 331 | 0.300 |
Why?
|
| Visual Perception | 3 | 2024 | 334 | 0.290 |
Why?
|
| Luteal Phase | 3 | 2010 | 14 | 0.290 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2019 | 7 | 0.280 |
Why?
|
| Neurosciences | 1 | 2009 | 51 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2001 | 353 | 0.280 |
Why?
|
| Binge Drinking | 2 | 2019 | 15 | 0.280 |
Why?
|
| Hemodynamics | 6 | 2014 | 713 | 0.280 |
Why?
|
| Reference Values | 6 | 2010 | 608 | 0.280 |
Why?
|
| Benzothiazoles | 1 | 2008 | 17 | 0.270 |
Why?
|
| Psychiatry | 1 | 2009 | 86 | 0.270 |
Why?
|
| Dopamine Agonists | 1 | 2008 | 27 | 0.270 |
Why?
|
| Smoking Prevention | 2 | 2012 | 46 | 0.260 |
Why?
|
| Acoustic Stimulation | 3 | 2016 | 130 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1229 | 0.260 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2006 | 49 | 0.260 |
Why?
|
| Risk Factors | 13 | 2024 | 5899 | 0.260 |
Why?
|
| Food Deprivation | 3 | 1992 | 23 | 0.250 |
Why?
|
| Genetic Association Studies | 4 | 2013 | 300 | 0.250 |
Why?
|
| Membrane Transport Proteins | 2 | 2005 | 169 | 0.250 |
Why?
|
| Introns | 2 | 2012 | 300 | 0.250 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2006 | 4 | 0.250 |
Why?
|
| Anxiety Disorders | 4 | 2015 | 155 | 0.240 |
Why?
|
| Fasting | 3 | 1992 | 163 | 0.240 |
Why?
|
| Naphthyridines | 1 | 2006 | 27 | 0.240 |
Why?
|
| Random Allocation | 3 | 2015 | 307 | 0.240 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 40 | 0.240 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2004 | 20 | 0.230 |
Why?
|
| Reversal Learning | 1 | 2025 | 18 | 0.230 |
Why?
|
| Learning | 2 | 2025 | 293 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 502 | 0.220 |
Why?
|
| Tomography, Emission-Computed | 6 | 1998 | 104 | 0.220 |
Why?
|
| Glutamic Acid | 1 | 2025 | 147 | 0.220 |
Why?
|
| Baclofen | 2 | 2002 | 16 | 0.220 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 171 | 0.220 |
Why?
|
| Memory Disorders | 2 | 2016 | 72 | 0.210 |
Why?
|
| Connectome | 1 | 2025 | 88 | 0.210 |
Why?
|
| Genetic Testing | 3 | 2017 | 565 | 0.210 |
Why?
|
| Self Disclosure | 2 | 2001 | 29 | 0.210 |
Why?
|
| Estrogens | 2 | 2022 | 195 | 0.210 |
Why?
|
| Association Learning | 2 | 2016 | 38 | 0.210 |
Why?
|
| Metacognition | 1 | 2023 | 8 | 0.200 |
Why?
|
| Blood Glucose | 6 | 2015 | 867 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 2 | 2016 | 115 | 0.200 |
Why?
|
| Consciousness | 1 | 2023 | 28 | 0.200 |
Why?
|
| Pilot Projects | 4 | 2024 | 917 | 0.200 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 444 | 0.200 |
Why?
|
| Nicotinic Antagonists | 1 | 2003 | 3 | 0.200 |
Why?
|
| Feedback | 1 | 2024 | 131 | 0.200 |
Why?
|
| Cell Adhesion Molecules | 3 | 2019 | 174 | 0.200 |
Why?
|
| Nerve Net | 3 | 2017 | 394 | 0.200 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1985 | 0.190 |
Why?
|
| Caudate Nucleus | 2 | 2019 | 15 | 0.190 |
Why?
|
| Aggression | 1 | 2006 | 330 | 0.190 |
Why?
|
| Serotonin Antagonists | 1 | 2002 | 24 | 0.190 |
Why?
|
| Risperidone | 1 | 2002 | 24 | 0.190 |
Why?
|
| Endocannabinoids | 2 | 2015 | 27 | 0.190 |
Why?
|
| Obesity | 3 | 2019 | 1018 | 0.190 |
Why?
|
| Drug Interactions | 5 | 2015 | 239 | 0.180 |
Why?
|
| Tryptophan | 1 | 2002 | 105 | 0.180 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2002 | 5 | 0.180 |
Why?
|
| Anger | 2 | 2015 | 80 | 0.180 |
Why?
|
| Eating | 2 | 2015 | 162 | 0.180 |
Why?
|
| History, 20th Century | 3 | 2014 | 314 | 0.180 |
Why?
|
| Psilocybin | 1 | 2021 | 3 | 0.180 |
Why?
|
| Drug Administration Schedule | 5 | 2006 | 829 | 0.180 |
Why?
|
| Attitude | 3 | 2009 | 132 | 0.180 |
Why?
|
| Functional Neuroimaging | 2 | 2019 | 32 | 0.180 |
Why?
|
| Carbon Radioisotopes | 1 | 2021 | 34 | 0.170 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2024 | 125 | 0.170 |
Why?
|
| Fentanyl | 2 | 1992 | 86 | 0.170 |
Why?
|
| Pentobarbital | 2 | 1992 | 16 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2014 | 187 | 0.170 |
Why?
|
| Environment | 3 | 2011 | 230 | 0.160 |
Why?
|
| Circadian Rhythm | 2 | 2015 | 285 | 0.160 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2010 | 124 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 203 | 0.160 |
Why?
|
| Financial Management | 1 | 2020 | 21 | 0.160 |
Why?
|
| Neurosecretory Systems | 1 | 2000 | 35 | 0.160 |
Why?
|
| Georgia | 1 | 2019 | 37 | 0.160 |
Why?
|
| GABA Modulators | 1 | 1999 | 8 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 57 | 0.150 |
Why?
|
| Automobile Driving | 1 | 2020 | 33 | 0.150 |
Why?
|
| Frontal Lobe | 2 | 2024 | 126 | 0.150 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2019 | 49 | 0.150 |
Why?
|
| Physical Stimulation | 1 | 2019 | 54 | 0.150 |
Why?
|
| Putamen | 1 | 2019 | 13 | 0.150 |
Why?
|
| Cell Phone | 1 | 2019 | 39 | 0.150 |
Why?
|
| Pursuit, Smooth | 1 | 1999 | 31 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 349 | 0.150 |
Why?
|
| Linkage Disequilibrium | 4 | 2020 | 478 | 0.150 |
Why?
|
| Rats | 7 | 2013 | 4072 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 24 | 0.140 |
Why?
|
| Norepinephrine | 2 | 2010 | 169 | 0.140 |
Why?
|
| Europe | 1 | 2019 | 337 | 0.140 |
Why?
|
| Addiction Medicine | 1 | 2018 | 2 | 0.140 |
Why?
|
| Saccades | 1 | 1999 | 75 | 0.140 |
Why?
|
| Haplotypes | 3 | 2009 | 647 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2013 | 49 | 0.140 |
Why?
|
| Animal Communication | 1 | 2018 | 13 | 0.140 |
Why?
|
| Hydromorphone | 1 | 2018 | 11 | 0.140 |
Why?
|
| Biomarkers | 4 | 2021 | 1910 | 0.140 |
Why?
|
| Capsules | 2 | 2008 | 38 | 0.140 |
Why?
|
| Illinois | 1 | 2019 | 520 | 0.140 |
Why?
|
| Varenicline | 2 | 2022 | 16 | 0.140 |
Why?
|
| Exploratory Behavior | 2 | 2009 | 48 | 0.140 |
Why?
|
| Corpus Striatum | 1 | 2018 | 83 | 0.130 |
Why?
|
| Ganglionic Stimulants | 1 | 2017 | 7 | 0.130 |
Why?
|
| Temporal Lobe | 1 | 2019 | 188 | 0.130 |
Why?
|
| Acetaminophen | 1 | 2018 | 61 | 0.130 |
Why?
|
| Feeding and Eating Disorders | 1 | 2020 | 185 | 0.130 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2017 | 8 | 0.130 |
Why?
|
| Nausea | 2 | 2012 | 93 | 0.130 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2017 | 15 | 0.130 |
Why?
|
| Probability | 3 | 2011 | 355 | 0.130 |
Why?
|
| Research Design | 2 | 2013 | 617 | 0.130 |
Why?
|
| Energy Metabolism | 2 | 1990 | 299 | 0.130 |
Why?
|
| Sucrose | 1 | 2017 | 64 | 0.130 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 456 | 0.130 |
Why?
|
| Spatial Behavior | 1 | 2017 | 20 | 0.130 |
Why?
|
| Facial Muscles | 2 | 2019 | 24 | 0.130 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2016 | 40 | 0.120 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 61 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2017 | 228 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1713 | 0.120 |
Why?
|
| Exercise Test | 1 | 2017 | 152 | 0.120 |
Why?
|
| Phentermine | 1 | 1996 | 4 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1931 | 0.120 |
Why?
|
| Fenfluramine | 1 | 1996 | 20 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2017 | 469 | 0.120 |
Why?
|
| Neuroprotective Agents | 1 | 1997 | 98 | 0.120 |
Why?
|
| Pimozide | 1 | 1996 | 3 | 0.120 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 65 | 0.120 |
Why?
|
| Neuropeptides | 1 | 2016 | 114 | 0.120 |
Why?
|
| Neurotransmitter Agents | 1 | 2016 | 102 | 0.120 |
Why?
|
| Acute Disease | 2 | 2012 | 841 | 0.120 |
Why?
|
| Paroxetine | 1 | 1995 | 26 | 0.120 |
Why?
|
| Dopamine Agents | 1 | 1996 | 32 | 0.120 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 18 | 0.120 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 401 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 71 | 0.110 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2015 | 29 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 239 | 0.110 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 87 | 0.110 |
Why?
|
| Glycerides | 1 | 2015 | 13 | 0.110 |
Why?
|
| Parent-Child Relations | 1 | 2015 | 80 | 0.110 |
Why?
|
| Arachidonic Acids | 1 | 2015 | 36 | 0.110 |
Why?
|
| Heterozygote | 1 | 2016 | 382 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2015 | 113 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2014 | 1261 | 0.110 |
Why?
|
| Alleles | 4 | 2018 | 1139 | 0.110 |
Why?
|
| Feeding Behavior | 2 | 2010 | 337 | 0.110 |
Why?
|
| Students | 2 | 2017 | 179 | 0.110 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 35 | 0.100 |
Why?
|
| Mental Processes | 1 | 2014 | 30 | 0.100 |
Why?
|
| Twin Studies as Topic | 2 | 2012 | 19 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2013 | 175 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 759 | 0.100 |
Why?
|
| Electric Stimulation | 1 | 2015 | 344 | 0.100 |
Why?
|
| Animals, Laboratory | 1 | 2013 | 25 | 0.100 |
Why?
|
| Mice | 4 | 2013 | 12269 | 0.100 |
Why?
|
| Suicidal Ideation | 2 | 2024 | 75 | 0.100 |
Why?
|
| Self Concept | 1 | 2013 | 136 | 0.100 |
Why?
|
| Bipolar Disorder | 2 | 2014 | 399 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 848 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1161 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 217 | 0.090 |
Why?
|
| Reinforcement, Social | 1 | 2012 | 1 | 0.090 |
Why?
|
| Homozygote | 1 | 2012 | 207 | 0.090 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.090 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 13 | 0.090 |
Why?
|
| Outpatients | 2 | 2011 | 104 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2023 | 86 | 0.090 |
Why?
|
| Administration, Inhalation | 2 | 2011 | 203 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2008 | 109 | 0.090 |
Why?
|
| Affective Symptoms | 1 | 2012 | 56 | 0.090 |
Why?
|
| Coffee | 2 | 2010 | 10 | 0.090 |
Why?
|
| Central Nervous System Sensitization | 1 | 2011 | 10 | 0.090 |
Why?
|
| Pain Measurement | 3 | 2009 | 373 | 0.090 |
Why?
|
| Receptors, Opioid, mu | 1 | 2011 | 49 | 0.090 |
Why?
|
| Injections, Intravenous | 3 | 2001 | 212 | 0.090 |
Why?
|
| Infusion Pumps | 1 | 2011 | 25 | 0.090 |
Why?
|
| Transdermal Patch | 1 | 2011 | 3 | 0.090 |
Why?
|
| Stroop Test | 1 | 2011 | 11 | 0.090 |
Why?
|
| Word Association Tests | 1 | 2011 | 5 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 218 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 180 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 493 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2012 | 297 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2017 | 3054 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2011 | 188 | 0.080 |
Why?
|
| Aged | 7 | 2018 | 20434 | 0.080 |
Why?
|
| Intelligence | 1 | 2011 | 67 | 0.080 |
Why?
|
| Receptors, Nicotinic | 1 | 2011 | 132 | 0.080 |
Why?
|
| Writing | 1 | 2011 | 29 | 0.080 |
Why?
|
| Placebo Effect | 2 | 2012 | 35 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 156 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 278 | 0.080 |
Why?
|
| Pharmacology | 1 | 2010 | 11 | 0.080 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2010 | 3 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2011 | 663 | 0.080 |
Why?
|
| ROC Curve | 1 | 2012 | 775 | 0.080 |
Why?
|
| Pregnenolone | 1 | 2009 | 1 | 0.080 |
Why?
|
| Desoxycorticosterone | 1 | 2009 | 18 | 0.080 |
Why?
|
| Species Specificity | 1 | 2011 | 684 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2012 | 494 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 391 | 0.080 |
Why?
|
| Substance Abuse Detection | 1 | 2009 | 11 | 0.080 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.080 |
Why?
|
| England | 1 | 2009 | 38 | 0.070 |
Why?
|
| Wakefulness | 1 | 2009 | 131 | 0.070 |
Why?
|
| Canada | 1 | 2009 | 194 | 0.070 |
Why?
|
| Character | 1 | 2008 | 6 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 20 | 0.070 |
Why?
|
| Computers | 1 | 2008 | 102 | 0.070 |
Why?
|
| Hunger | 2 | 2003 | 20 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2018 | 159 | 0.070 |
Why?
|
| Psychometrics | 3 | 2012 | 337 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 893 | 0.070 |
Why?
|
| Logistic Models | 1 | 2011 | 1243 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2010 | 175 | 0.070 |
Why?
|
| Cotinine | 3 | 2004 | 15 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2014 | 203 | 0.070 |
Why?
|
| Temperament | 1 | 2007 | 28 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 170 | 0.070 |
Why?
|
| Chicago | 1 | 2012 | 1464 | 0.070 |
Why?
|
| United States | 3 | 2024 | 7622 | 0.070 |
Why?
|
| Games, Experimental | 1 | 2007 | 11 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 624 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2008 | 131 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2006 | 46 | 0.060 |
Why?
|
| Isoindoles | 1 | 2006 | 13 | 0.060 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2006 | 6 | 0.060 |
Why?
|
| Verbal Learning | 1 | 2006 | 30 | 0.060 |
Why?
|
| Indoles | 1 | 2008 | 303 | 0.060 |
Why?
|
| Deoxyglucose | 3 | 1991 | 39 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 920 | 0.060 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2006 | 42 | 0.060 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2006 | 39 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 64 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 80 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1103 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2016 | 9099 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2006 | 300 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1264 | 0.060 |
Why?
|
| Reinforcement Schedule | 3 | 2006 | 16 | 0.060 |
Why?
|
| Models, Animal | 1 | 2006 | 282 | 0.060 |
Why?
|
| 3' Untranslated Regions | 1 | 2005 | 98 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2009 | 1245 | 0.050 |
Why?
|
| Touch | 1 | 2005 | 51 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2024 | 40 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 894 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2006 | 164 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 531 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 754 | 0.050 |
Why?
|
| Brain Concussion | 1 | 2024 | 86 | 0.050 |
Why?
|
| Time Perception | 1 | 2003 | 23 | 0.050 |
Why?
|
| Multifactorial Inheritance | 2 | 2015 | 202 | 0.050 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 578 | 0.050 |
Why?
|
| Equipment and Supplies | 1 | 2003 | 32 | 0.050 |
Why?
|
| Morphine | 1 | 2004 | 128 | 0.050 |
Why?
|
| Causality | 1 | 2003 | 82 | 0.050 |
Why?
|
| Cholinergic Agents | 1 | 2022 | 17 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2024 | 140 | 0.050 |
Why?
|
| Plant Structures | 1 | 2002 | 3 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1531 | 0.040 |
Why?
|
| Glucose | 2 | 1998 | 692 | 0.040 |
Why?
|
| Beverages | 1 | 2001 | 16 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 63 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 57 | 0.040 |
Why?
|
| Antiemetics | 1 | 2001 | 28 | 0.040 |
Why?
|
| Serotonin | 1 | 2002 | 209 | 0.040 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 31 | 0.040 |
Why?
|
| Auditory Perception | 1 | 2001 | 104 | 0.040 |
Why?
|
| Fluorine Radioisotopes | 2 | 1991 | 26 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 168 | 0.040 |
Why?
|
| Half-Life | 1 | 1999 | 93 | 0.040 |
Why?
|
| Confusion | 2 | 1991 | 9 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 1999 | 149 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3502 | 0.040 |
Why?
|
| Electrooculography | 1 | 2019 | 21 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2024 | 10164 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 1999 | 34 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 1999 | 40 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 82 | 0.040 |
Why?
|
| Electromyography | 1 | 2019 | 198 | 0.040 |
Why?
|
| Body Weight | 2 | 2006 | 449 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 1990 | 149 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 50 | 0.030 |
Why?
|
| Judgment | 1 | 1999 | 69 | 0.030 |
Why?
|
| Candy | 1 | 2017 | 3 | 0.030 |
Why?
|
| Connecticut | 1 | 2017 | 26 | 0.030 |
Why?
|
| Appetitive Behavior | 1 | 1997 | 14 | 0.030 |
Why?
|
| Drinking | 1 | 1997 | 34 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 282 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 188 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 197 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1997 | 174 | 0.030 |
Why?
|
| Universities | 1 | 2017 | 150 | 0.030 |
Why?
|
| Gambling | 1 | 1999 | 168 | 0.030 |
Why?
|
| Premedication | 1 | 1996 | 57 | 0.030 |
Why?
|
| Neuroticism | 1 | 2015 | 5 | 0.030 |
Why?
|
| Guanylate Kinases | 1 | 2015 | 12 | 0.030 |
Why?
|
| Visual Analog Scale | 1 | 2015 | 18 | 0.030 |
Why?
|
| Peptides | 1 | 2019 | 656 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1917 | 0.030 |
Why?
|
| Ghrelin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 100 | 0.030 |
Why?
|
| Gender Identity | 1 | 1994 | 58 | 0.030 |
Why?
|
| Protective Agents | 1 | 2014 | 34 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 304 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 132 | 0.020 |
Why?
|
| Somatosensory Cortex | 1 | 2014 | 116 | 0.020 |
Why?
|
| Nordazepam | 1 | 1993 | 1 | 0.020 |
Why?
|
| Signal Detection, Psychological | 1 | 2013 | 19 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 315 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 696 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 985 | 0.020 |
Why?
|
| Nitrous Oxide | 1 | 1993 | 107 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 16 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1992 | 33 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2013 | 113 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1992 | 99 | 0.020 |
Why?
|
| Autoradiography | 1 | 1991 | 53 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 97 | 0.020 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 98 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 1991 | 15 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 203 | 0.020 |
Why?
|
| Hibernation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Physiological Phenomena | 1 | 2010 | 7 | 0.020 |
Why?
|
| Respiration | 1 | 1992 | 269 | 0.020 |
Why?
|
| Androstane-3,17-diol | 1 | 2009 | 3 | 0.020 |
Why?
|
| Androsterone | 1 | 2009 | 5 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 4 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 41 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2009 | 111 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2009 | 145 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3911 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 1006 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3830 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 30 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2008 | 45 | 0.020 |
Why?
|
| Radiography | 1 | 1990 | 790 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1190 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7061 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 970 | 0.020 |
Why?
|
| Feedback, Psychological | 1 | 2006 | 20 | 0.020 |
Why?
|
| Quinolinic Acid | 1 | 2006 | 3 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2006 | 40 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 543 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 887 | 0.010 |
Why?
|
| Adenosine | 1 | 2008 | 275 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 116 | 0.010 |
Why?
|
| Hybrid Vigor | 1 | 2003 | 1 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2003 | 144 | 0.010 |
Why?
|
| Threonine | 1 | 2003 | 33 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2003 | 31 | 0.010 |
Why?
|
| Corticosterone | 1 | 2003 | 35 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 189 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 3435 | 0.010 |
Why?
|
| Cysteine | 1 | 2003 | 145 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1799 | 0.010 |
Why?
|
| Ipecac | 1 | 2001 | 2 | 0.010 |
Why?
|
| Emetics | 1 | 2001 | 3 | 0.010 |
Why?
|
| Ondansetron | 1 | 2001 | 8 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 1265 | 0.010 |
Why?
|
| Vomiting | 1 | 2001 | 108 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 356 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2000 | 102 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 621 | 0.010 |
Why?
|